![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Abstract
Aim of this study was to evaluate the efficacy of ospemifene in the prevention of recurrent lower urinary tract infections in postmenopausal women with vulvovaginal atrophy. The study have a retrospective design. Thirty-nine patients were enrolled. Patients underwent clinical examination and urine culture. The urinary symptoms and the quality of life were evaluated with UTISA score, PUF and SF-36 questionnaires before and after treatment. All 39 patients received ospemifene 60 mg one tablet/daily for 6 months. Adverse effects and complications were assessed. Thirty-nine patients were enrolled in the study. Two patients experienced one new UTI episode and the mean number of positive urine culture decreased significantly after 6 months (3.65 ± 2.12 vs 0.25 ± 0.17, p < .0001). The mean number of urinary infection symptoms decreased significantly after treatment; dysuria reduced (4.76 ± 2.45 vs 0.89 ± 1.12). PUF score and SF-36 showed a statistically significant change (22.43 ± 5.89 vs 12.14 ± 3.21) and (52.86 ± 9.21 vs 83.43 ± 10.76). No adverse effects were reported and the total success rate was the 92.3% after 6 months at PGI-I. Ospemifene is a valid alternative with excellent tolerability for the UTIS prevention in postmenopausal patients.
Chinese abstract
本研究的目的是评估奥培米芬预防绝经后妇女外阴阴道萎缩反复下尿路感染的疗效。这项研究是一个回顾性的设计, 三十九名患者入选, 患者接受临床检查和尿培养。采用UTISA评分、PUF和SF-36问卷评估治疗前后尿路症状和生活质量。所有39名患者接受奥培米芬60 mg/日, 持续6个月；评估不良反应和并发症。39名患者参加了这项研究, 2例患者发生一次新的尿路感染, 尿培养阳性的平均次数在6个月后显著下降（3.65 ± 2.12 vs 0.25 ± 0.17, p <.0001）。治疗后尿路感染症状平均次数明显减少; 排尿困难减少（4.76 ± 2.45 vs 0.89 ± 1.12）；PUF评分和SF-36分别为（22.43 ± 5.89 vs 12.14 ± 3.21）和（52.86 ± 9.21 vs 83.43 ± 10.76）。PGI-I治疗6个月后无不良反应, 总成功率为92.3%。奥培米芬是绝经后妇女预防UTIS的良好耐受性的有效选择方法。
Disclosure statement
The authors report no conflicts of interest.